ACT 017

Drug Profile

ACT 017

Alternative Names: ACT 017

Latest Information Update: 13 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Acticor Biotech
  • Class Monoclonal antibodies
  • Mechanism of Action Glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Stroke

Most Recent Events

  • 07 Feb 2017 Acticor Biotech plans a first-in-human phase I trial in Stroke in Netherlands
  • 22 Nov 2016 Acticor Biotech and Mediolanum farmaceutici initiate collaboration on the development of ACT 017
  • 12 Jul 2016 Preclinical trials in Stroke in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top